<--start of Unibot Ad Code--> <--end of Unibot Ad Code-->

Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20
BW Businessworld

Novartis Immuno-Oncology Drug Candidate Fails Skin Cancer Trial

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.

Photo Credit :

1474268333_swxPPS_Novartis_Pharma_Reu.jpg

Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer.

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.

Despite the failure, Novartis is continuing development of spartalizumab, a so-called checkpoint inhibitor thought to help take the brakes off the immune system in fighting cancer, against other kind of tumors, the Basel-based company said.

Novartis has been late in developing such immuno-oncology drugs for its portfolio, a field now dominated by lucrative medicines including Merck's Keytruda, Bristol-Myers Squibb's Opdivo, and to a lesser extent, Roche's Tecentriq.

(Reuters)


Tags assigned to this article:
novartis drugmaker healthcare skin cancer Immuno-Oncology